Cytoran Plus Mechanism of Action

Pharmacotherapeutic group: Pantoprazole: Proton pump inhibitors, ATC code: A02BC02.
Domperidone: Domperidone is a peripheral dopamine (D2) and (D3) receptor antagonist, ATC Code: A03FA03.
Pharmacology: Mechanism of Action: Pantoprazole, a benzimidazole sulphoxide derived prodrug, is an irreversible proton pump inhibitor. Pantoprazole, being a weak base, is highly ionized at low pH and readily accumulated in the highly acidic canalicular lumen of the stimulated parietal cell in the stomach. In this acidic environment, it is protonated and rapidly converted to a cationic cyclic sulphonamide. The sulphonamide binds covalently to cysteine residues on the luminal (acidic) surface of H+/K+-ATPase to form a mixed disulphide; thus causing irreversible inhibition of the gastric proton pump. This inhibition of the gastric proton pump or H+ / K+ -ATPase (which represents the final step in the secretory process), suppress gastric acid secretion.
Domperidone, a benzimidazole derivative (structurally related to the butyrophenones), acts by selectively antagonizing the peripheral dopaminergic 0, receptors in the gastrointestinal (G.I.) wall, thereby enhancing gastrointestinal peristalsis and motility and increasing Lower Esophageal Sphincter (LES) tone.
Pharmacokinetics: Pantoprazole: Pantoprazole is rapidly absorbed after oral administration, with peak plasma concentrations (C_max) of 1.1 to 3.1 (mean 2.1) m/L occurring within 2 to 4 (mean 2.7) hours (tmax) after ingestion of an enteric coated 40 mg tablet. The volume of distribution is low (mean 0.16 L/kg at steady state) due to high degree of plasma protein binding (-98%). Plasma Pantoprazole concentrations decline monophasically after oral administration, with a mean plasma terminal half-life (ty,P) of 0.9 to 1.9 hours. However, since inhibition of acid secretion is non-competitive or irreversible, there is no correlation between plasma levels and the duration of action of Pantoprazole. Concomitant intake of food has no influence on the bioavailability of Pantoprazole, and any possible retardant effect of food on the rate of drug absorption is not of clinical relevance, considering the prolonged antisecretory action of Pantoprazole. The enteric coating does not influence the bioavailability of Pantoprazole. Pantoprazole undergoes extensive hepatic metabolism via cytochrome P450 oxidase followed by sulphate conjugation. Elimination of Pantoprazole is predominantly renal, with -80% of an oral dose being excreted as urinary metabolite; the remainder is excreted in the feces and originates primary from biliary secretion.
Domperidone: Domperidone is rapidly and almost completely (93%) absorbed after oral administration. Peak plasma concentrations occur within 30 min. after oral administration. The peak plasma concentration value after a 20 mg oral dose is in the range of 15 to 19 ng/ml. The mean elimination half-life ranges from 12-16 hours for an oral dose. Oral bioavailability of Domperidone is 13-17% because of extensive presystemic metabolism in gut wall and liver. Administration of Domperidone 90 minutes after a meal increases bioavailability whereas Cimetidine or alkali pretreatment reduces bioavailability. Domperidone is strongly bound to olasma proteins (90-93%). Domperidone undergoes extensive biotransformation with <1% excreted unchanged in urine.
Special populations: Pantoprazole: Hepatic impairment: There is a slight increase (1.5 fold) in a maximum drug concentrations in patients with mild to severe hepatic impairment. No dosage adjustment is needed in patients with mild to severe hepatic impairment.
Renal impairment: Pharmacokinetic parameters for Pantoprazole in patients with severe renal impairment are similar to those of healthy subjects. No dosage adjustment is needed in patients with renal impairment.
Gender: No dosage adjustment is needed based on gender.
Pediatrics: The pharmacokinetics of Pantoprazole have not been investigated in patients <18 years of age.
Geriatrics: No dosage adjustment is recommended based on age.
Domperidone: Hepatic impairment: There is no published pharmacokinetic data in patients with hepatic impairment. Because Domperidone is extensively metabolized, response to the drug should be carefully monitored in this patient population.
Neonates: Domperidone is not recommended for use in neonates.
Breast milk: Domperidone may precipitate galactorrhea and improve postnatal lactation. It is secreted in breast milk in very small quantities and thus insufficient to be considered harmful.
Pediatrics: Domperidone is not recommended other than for treatment of nausea and vomiting in patients undergoing cancer therapy. There may be an increased risk for extrapyramidal reactions in young children because of an incompletely developed blood brain barrier.
Pregnant women: The safety of Domperidone has not been proven, therefore its use is not recommended in pregnant women.
Geriatrics: No special precautions are necessary in older patients. Pantoprazole + Domperidone should be used with caution in conditions where the individual drugs have been used with precautionary approach.